Andreas Bierl

AMGEN GmbH develops, manufactures, and markets human therapeutics based on cellular biology. It was established to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen & Aranesp for the treatment of anemia in people with chronic kidney disease; Neupogen & Neulasta to help restore white blood cell counts for cancer patients and Enbrel for the treatment of psoriasis and rheumatoid arthritis. The company was founded in 1980 and is headquartered in Munich, Germany.

AMGEN GmbH develops, manufactures, and markets human therapeutics based on cellular biology. It was established to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen & Aranesp for the treatment of anemia in people with chronic kidney disease; Neupogen & Neulasta to help restore white blood cell counts for cancer patients and Enbrel for the treatment of psoriasis and rheumatoid arthritis. The company was founded in 1980 and is headquartered in Munich, Germany.

AMGEN GmbH develops, manufactures, and markets human therapeutics based on cellular biology. It was established to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen & Aranesp for the treatment of anemia in people with chronic kidney disease; Neupogen & Neulasta to help restore white blood cell counts for cancer patients and Enbrel for the treatment of psoriasis and rheumatoid arthritis. The company was founded in 1980 and is headquartered in Munich, Germany.